J&J paid $1 billion in cash for Firefly Bio and its Firelink degrader antibody conjugate platform — a KRAS bet placed at exactly the right moment.
Firefly built Firelink to combine antibody drug conjugates and protein degraders, delivering selective protein degradation directly to tumor cells while sparing healthy tissue. J&J’s target is KRAS-driven cancers, where patients face survival measured in months. “KRAS has notoriously been considered an undruggable target,” said John Reed, J&J’s EVP of innovative medicine R&D, in Monday’s acquisition announcement.
Firefly was co-founded by Carolyn Bertozzi, the Stanford chemist who won the 2022 Nobel Prize in Chemistry. Its $94 million Series A in 2024 drew Versant Ventures, MPM BioImpact, Decheng Capital, and Eli Lilly. J&J’s $1 billion is roughly 10x Firefly’s Series A, for a platform that’s still preclinical. On the same day, Roche committed $700 million upfront to partner Nurix Therapeutics on its BTK degrader bexobrutideg: degrader deals are pricing up across the board.
What J&J actually bought is a KRAS thesis timed to Revolution Medicines’ April 2026 data, where daraxonrasib doubled pancreatic cancer survival to 13.2 months versus chemotherapy. That result made KRAS a race. Firefly’s DAC approach targets protein degradation at the tumor rather than kinase inhibition, a mechanistically distinct shot at the same patients. It’s a platform bet before the field has time to price in the differentiation.
Deal closes later in 2026.
Diana Kowalski